Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: A double-blind, randomized, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 550-554

  Kordon, Andreas ^a   Wahl, Karina ^a   Koch, Nicole ^a   Zurowski, Bartosz ^a   Anlauf, Matthias ^a   Vielhaber, Kirsten ^b   Kahl, Kai G ^a   Broocks, Andreas ^c   Voderholzer, Ulrich ^b   Hohagen, Fritz ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HELIOS KLINIKEN SCHWERIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; APATHY; ARTICLE; ATTENTION DISTURBANCE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DYSPEPSIA; EVENING DOSAGE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; MALE; MORNING DOSAGE; NAUSEA; NIGHTMARE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; UPPER ABDOMINAL PAIN; VERTIGO; XEROSTOMIA; ADOLESCENT; AGED; DOSE RESPONSE; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 58149112927     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318185e735     Document Type: Article

References (20)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association; 2007.
2. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive- compulsive disorder. Mol Psychiatry. 2006;11:622-632.
3. Toren P, Rainer S, Laor N, et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf. 2004;27:1135-1156.
4. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002;63(8):700-703.
5. Mohr N, Vythilingum B, Emsley RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2002;17(1):37-40.
6. Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. JClinPsychopharmacol. 2003;23(5):448-450.
7. Misri S, Milis L. Obsessive-compulsive disorder in the postpartum: openlabel trial of quetiapine augmentation. J Clin Psychopharmacol. 2004; 24(6):624-627.
8. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17(3):115-119.
9. Denys D, de Geus F, van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive- compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(8):1040-1048.
10. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-233.
11. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
12. Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a doubleblind, randomised, placebo-controlled study. BMC Psychiatry. 2005;5(1):5.
13. Fineberg NA, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005;20(4):223-226.
14. Denys D, Fineberg N, Carey D, et al. Quetiapine addition in obsessive- compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61:412-414.
15. Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21(6):337-343.
16. Leckmann JF, Riddle MA, et al. The Yale Global Tic Severity Scale: Initial Testing of a Clinican Rated Scale of Tic Severity. Am Acad Child Adolescent Psychiatry. 1988;28(4):566-573.
17. Hamilton M. A Rating Scale for Depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
18. Hautzinger M, Bailer M, Worall H, et al. Beck Depression-Inventar. Bern: Huber; 1995.
19. Bullinger M, Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe; 1998.
20. Summerfeldt LJ, Richter MA, Antony MM, et al. Symptom structure in obsessive-compulsive disorder: a confirmatory factor-analytic study. BehavRes Ther. 1999;37(4):297-311.